All In Biotech

NDA 019835 · Kenvue Brands

Zyrtec Hives

Cetirizine Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Dec 8, 1995

Approved uses

4

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

31,596

24,286 serious, 5,136 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 13, 2026.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ZYRTEC HIVES · CETIRIZINE HYDROCHLORIDE 10MG · TABLET, ORAL · Discontinued
  • ZYRTEC ALLERGY · CETIRIZINE HYDROCHLORIDE 10MG · TABLET, ORAL · Over-the-counter
  • ZYRTEC HIVES · CETIRIZINE HYDROCHLORIDE 5MG · TABLET, ORAL · Discontinued
  • ZYRTEC ALLERGY · CETIRIZINE HYDROCHLORIDE 5MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,579
  • pain8,991
  • fatigue8,958
  • alopecia7,543
  • rheumatoid arthritis7,476
  • abdominal discomfort7,454
  • systemic lupus erythematosus7,162
  • pemphigus7,032
  • off label use6,788
  • rash6,699
  • glossodynia6,534
  • swelling6,095

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200560
200620
200766
2008176
2009162
2010138
2011138
2012169
2013243
2014263
2015381
2016833
2017894
20181,027
20191,560
20202,161
20214,406
20224,409
20233,424
20244,292
20254,069
20262,686

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Kenvue Brands · Also marketed as Zyrtec Allergy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.